```markdown ## Section 4: CNS Pharmacology - 1: Sedative-Hypnotics and Anxiolytics Sedative-hypnotics and anxiolytics are central nervous system (CNS) depressants primarily used to reduce anxiety (anxiolysis), induce sedation (calmness without sleep), and promote sleep (hypnosis). The choice of agent depends on the specific indication, desired duration of action, and safety profile. **Major Drug Classes & Mechanisms:** 1. **Benzodiazepines (BZDs - e.g., diazepam, lorazepam, alprazolam, temazepam):** The most widely used class. They potentiate the effect of the inhibitory neurotransmitter GABA at GABA_A receptors by increasing the *frequency* of chloride channel opening. This hyperpolarizes neurons, reducing excitability. Effects range from anxiolysis (lower doses) to sedation, hypnosis, muscle relaxation, and anticonvulsant activity (higher doses). They are first-line for acute anxiety, panic disorder, muscle spasms, alcohol withdrawal, and as pre-anesthetic medication. Short/intermediate-acting BZDs (e.g., temazepam) are used for insomnia. 2. **Non-Benzodiazepine Hypnotics ("Z-drugs" - e.g., zolpidem, zaleplon, eszopiclone):** Structurally distinct from BZDs but act selectively on specific subtypes (ω1) of the GABA_A receptor, primarily promoting *hypnosis* with less effect on anxiety or muscle relaxation. Used almost exclusively for short-term management of insomnia. Zolpidem/eszopiclone aid sleep maintenance; zaleplon is ultra-short acting for sleep onset. 3. **Barbiturates (e.g., phenobarbital, secobarbital):** Largely replaced due to significant drawbacks. They also potentiate GABA_A receptors but by increasing the *duration* of chloride channel opening. They have a low therapeutic index (narrow safety margin), cause profound CNS depression (including respiratory depression), induce potent hepatic drug-metabolizing enzymes, and carry high abuse/dependence potential. Current use is limited to specific seizure disorders (phenobarbital) and rarely in anesthesia. 4. **Other Agents:** * **Buspirone:** A partial agonist at serotonin 5-HT_1A receptors. Provides anxiolysis *without* significant sedation, muscle relaxation, or abuse potential. Onset is slow (weeks), making it suitable only for Generalized Anxiety Disorder (GAD). * **Melatonin Receptor Agonists (e.g., ramelteon):** Activate MT₁/MT₂ receptors in the suprachiasmatic nucleus to regulate the sleep-wake cycle. Used for insomnia characterized by difficulty with sleep *onset*. * **Orexin Receptor Antagonists (e.g., suvorexant):** Block orexin (hypocretin) neuropeptides that promote wakefulness. Used for insomnia involving both sleep onset and maintenance. **Key Adverse Effects & Considerations:** * **CNS Depression:** Drowsiness, dizziness, confusion, impaired coordination, and memory (anterograde amnesia with BZDs) are common. Risk increases with dose and concomitant use of alcohol or other CNS depressants. * **Tolerance & Dependence:** Physical dependence and tolerance (requiring higher doses for the same effect) develop with regular use of BZDs, Z-drugs, and barbiturates. **Withdrawal** upon abrupt discontinuation can be severe (anxiety rebound, insomnia, tremors, seizures - particularly with short-acting agents or barbiturates). Tapering is essential. * **Respiratory Depression:** A critical risk, especially with barbiturates and high doses of BZDs, potentially fatal in overdose or with other depressants. * **Paradoxical Reactions:** Agitation or aggression can occur, especially in children/elderly with BZDs. * **"Z-drug" Specific:** Complex sleep-related behaviors (e.g., sleepwalking, sleep-driving) have been reported. * **Overdose Antidote:** **Flumazenil** is a competitive BZD receptor antagonist used to reverse BZD/Z-drug overdose (but can precipitate withdrawal in dependent patients; ineffective against barbiturates). ```

1: Introduction to pharmacology

The quiz will be on the following text — learn it for the best chance to win.